Arkolith/Insider Trading/RVNC/Form 4

Foley Mark J

CEO, DirectorRevance Therapeutics, Inc. (RVNC) · full profile →Form 4 · filed Aug 4, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$593K
Net Open-Market Flow
-$593K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 3, 2023Sell(S)26K$22.57$593K840K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001479290-23-000084) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML